Status:
COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
Lead Sponsor:
VA Office of Research and Development
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Brief Summary
The investigators are examining the activation of insulin signaling factors in skeletal muscles of human diabetics. The investigators are characterizing the defects in signaling, and are examining the...
Detailed Description
We have provided clear evidence that insulin activation of all three signaling components, Viz., IRS-1-dependent PI 3-Kinase, atypical protein kinase C (aPKC) and PKB/Akt is defective in diabetic musc...
Eligibility Criteria
Inclusion
- Stable uncomplicated type 2 diabetes
- Able to be off oral treatments for 2 months
Exclusion
- Diabetic complications related to heart, eye, nerve problems
- Renal impairment
- Cardiovascular disease
- Hepatic disease
- Prior history of other disorders or complications caused by diseases
- Insulin therapy needed
Key Trial Info
Start Date :
May 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT00690755
Start Date
May 1 2000
End Date
September 1 2012
Last Update
May 19 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center
Tampa, Florida, United States, 33612